Business Description
Delcath Systems Inc
NAICS : 621511
SIC : 8071
ISIN : US24661P6097
Total Employee Number:
156Description
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 98.46 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.75 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 17.85 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 133.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 22.76 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.16 | |||||
9-Day RSI | 50.54 | |||||
14-Day RSI | 55.19 | |||||
3-1 Month Momentum % | 8.55 | |||||
6-1 Month Momentum % | 10.39 | |||||
12-1 Month Momentum % | 4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.24 | |||||
Quick Ratio | 10.33 | |||||
Cash Ratio | 8.35 | |||||
Days Inventory | 278.81 | |||||
Days Sales Outstanding | 56.04 | |||||
Days Payable | 83.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -51.1 | |||||
Shareholder Yield % | 1.01 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 85.97 | |||||
Operating Margin % | -1.79 | |||||
Net Margin % | 0.62 | |||||
EBITDA Margin % | -1.33 | |||||
FCF Margin % | 21.18 | |||||
OCF Margin % | 23.36 | |||||
ROE % | 0.54 | |||||
ROA % | 0.49 | |||||
ROIC % | -2.44 | |||||
3-Year ROIIC % | 220.09 | |||||
ROC (Joel Greenblatt) % | -6.89 | |||||
ROCE % | -1.52 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 1287 | |||||
Forward PE Ratio | 231.25 | |||||
PE Ratio without NRI | 1287 | |||||
PS Ratio | 5.53 | |||||
PB Ratio | 3.94 | |||||
Price-to-Tangible-Book | 3.93 | |||||
Price-to-Free-Cash-Flow | 26.81 | |||||
Price-to-Operating-Cash-Flow | 24.24 | |||||
EV-to-EBIT | -219.83 | |||||
EV-to-EBITDA | -295.11 | |||||
EV-to-Revenue | 3.94 | |||||
EV-to-Forward-Revenue | 3.53 | |||||
EV-to-FCF | 18.54 | |||||
Price-to-GF-Value | 0.34 | |||||
Price-to-Graham-Number | 14.93 | |||||
| Price-to-Net-Current-Asset-Value | 4.1 | |||||
| Price-to-Net-Cash | 5.74 | |||||
Earnings Yield (Greenblatt) % | -0.45 | |||||
FCF Yield % | 4.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Delcath Systems Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 77.785 | ||
| EPS (TTM) (€) | 0.009 | ||
| Beta | 0.2067 | ||
| 3-Year Sharpe Ratio | 0.65 | ||
| 3-Year Sortino Ratio | 1.21 | ||
| Volatility % | 33.34 | ||
| 14-Day RSI | 55.19 | ||
| 14-Day ATR (€) | 0.427746 | ||
| 20-Day SMA (€) | 11.13335 | ||
| 12-1 Month Momentum % | 4 | ||
| 52-Week Range (€) | 7.2 - 12.1 | ||
| Shares Outstanding (Mil) | 34.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Delcath Systems Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Delcath Systems Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:30 | In 111 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 110 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:30 | In 21 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 20 days | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 | 9.42 (+1.20%) | ||
| General meeting for 2026 | 2026-05-13 10:00 | 9.62 (+3.82%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 9.57 (-1.58%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 9.57 (-1.58%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 08:30 | 8.55 (+2.40%) | ||
| Annual report for 2025 | 2026-02-26 | 8.55 (+2.40%) |
Show
Entries
Delcath Systems Inc Frequently Asked Questions
What is Delcath Systems Inc(STU:DV3R)'s stock price today?
The current price of STU:DV3R is €11.20. The 52 week high of STU:DV3R is €12.10 and 52 week low is €7.20.
When is next earnings date of Delcath Systems Inc(STU:DV3R)?
The next earnings date of Delcath Systems Inc(STU:DV3R) is 2026-08-06 Est..
Does Delcath Systems Inc(STU:DV3R) pay dividends? If so, how much?
Delcath Systems Inc(STU:DV3R) does not pay dividend.
Press Release
Articles on Delcath Systems Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers